RNS Number : 3333B
Proximagen Group PLC
16 April 2012
16 April 2012
Proximagen Group plc (the "Company")
Annual Report and Accounts
The Company confirms that further to sending the Annual Report and Accounts for the year ended 30 November 2011 to shareholders on 12 April 2012, an electronic copy of the Annual Report and Accounts is available in the Investor section of the Company's website at www.proximagen.com.
Proximagen Group plc Tel: +44 (0)20 7400 7700
James Hunter, Finance Director
Singer Capital Markets (Nominated Tel: +44 (0)20 3205 7500
Shaun Dobson/Claes Spang
M:Communications (Media enquiries) Tel: +44 (0)20 7920 2330
Mary-Jane Elliott / Mary Clark email@example.com
/ Hollie Vile
Proximagen Group plc (AIM:PRX) is a European biotechnology
company focused on the development and commercialisation
of novel therapeutics for diseases of the central nervous
system (CNS) and inflammation.
The Company is developing potential new best-in-class therapeutics
in its core disease areas including epilepsy, Parkinson's
disease, and Alzheimer's disease, as well as in other areas
such as inflammation, oncology and neuropathic pain.
Proximagen has a number of existing partnerships with pharmaceutical
companies including GlaxoSmithKline, Upsher-Smith and Lundbeck,
and is developing a broad pipeline of drug candidate programmes,
with four programmes in clinical development and more than
ten earlier stage assets being progressed.
Proximagen's strategy is to advance its pipeline with its
partners and to acquire innovative drug candidates that
complement its pipeline, with the objective of scaling
up its risk-mitigated operating model and generating sustainable
For more information, please visit www.proximagen.com.
This information is provided by RNS
The company news service from the London Stock Exchange